series-c-plus
Stage
4
Investors
About
Cyteir Therapeutics is a clinical-stage oncology company developing CYT-0851, an oral drug candidate targeting monocarboxylate transporters, currently in Phase 1/2 trials for advanced ovarian cancer in combination with chemotherapy agents.
Explore Cyteir Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.